J&J Highlights FDA Approval of STELARA® for Pediatric Crohn’s Disease The U.S. Food and Drug Administration (FDA) has approved STELARA (ustekinumab) for the treatment of pediatric patients aged two years and older with moderately to severely active Crohn’s disease (CD).…
Outfront Health Names Dr. Shane Speirs as Chief Medical Officer Outfront Health has announced the appointment of Shane Speirs, MD, MBA, as its new Chief Medical Officer (CMO), a strategic leadership move aimed at strengthening the company’s clinical direction and…
FDA Advisory Committee Backs TRUQAP® (capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee has delivered a largely favorable assessment of TRUQAP, an investigational targeted therapy developed by AstraZeneca, when used in…
Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on advancing differentiated therapies across neuroscience, inflammation, and immunology (NI&I) indications, has announced encouraging…
TRexBio Initiates Phase 1b Study of TRB-061 in Moderate-to-Severe Atopic Dermatitis with First Patient Dosed TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on discovering and developing immunoregulatory therapies rooted in tissue regulatory T cell (Treg) biology, has announced…
Convergent Therapeutics Appoints Andrew Davis as Chief Business and Strategy Officer Convergent Therapeutics, a clinical-stage biotech company dedicated to advancing next-generation radiopharmaceutical therapies for cancer, has announced the appointment of Andrew Davis as its Chief Business and Strategy Officer. The…
ClearNote Health to Showcase Leading Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 ClearNote Health, a biotechnology company focused on advancing early cancer detection, has announced an extensive lineup of presentations for the upcoming Digestive…
Ray Therapeutics Secures PRIME Designation from the European Medicines Agency for RTx-015 Targeting Retinitis Pigmentosa Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company focused on developing innovative therapies for vision restoration, has announced that the European Medicines Agency (EMA) has granted…
Sapient Unveils Advanced Tumor Protein Mapping Platform to Decode Functional Biology Across Key Dimensions in Human Cancers Sapient, an emerging leader in multi-omics data generation and biomarker discovery, has unveiled a major advancement in translational oncology research with the launch…
GSK Reports U.S. Food and Drug Administration Grants Breakthrough Therapy Designation and Priority Review Acceptance for Bepirovirsen in Chronic Hepatitis B as Potential First-in-Class Treatment Ionis Pharmaceuticals and its partner GSK have reached a significant regulatory milestone in the development…
Janux Therapeutics Halts Development of JANX008 Program Janux Therapeutics, Inc. has announced its decision to discontinue further clinical development of JANX008, an investigational EGFR-targeted Tumor Activated T Cell Engager (TRACTr) therapy, following completion of early-stage clinical evaluation and an internal…
Supported by Over $1 Billion in Investment, PCI Pharma Services Unveils Major Expansion of U.S. Sterile Fill-Finish and Drug–Device Combination Capabilities PCI Pharma Services has unveiled an extensive series of infrastructure investments aimed at significantly strengthening its sterile fill-finish capabilities…